Tasipimidine

Tasipimidine
Clinical data
Trade names	Tessie
Other names	ODM-105; ODM105; ORM-19695; ORM19695
Routes of; administration	Dogs: Oral; Humans: unspecified
Drug class	α2A-Adrenergic receptor agonist; Anxiolytic; Sedative; Hypnotic
Identifiers
	IUPAC name 2-(5-methoxy-3,4-dihydro-1H-isochromen-1-yl)-4,5-dihydro-1H-imidazole;
CAS Number	1465908-70-6;
PubChem CID	71767208;
ChemSpider	64835228;
UNII	QX8MJH6HGK;
KEGG	D11635;
ChEMBL	ChEMBL4594267;
Chemical and physical data
Formula	C13H16N2O2
Molar mass	232.283 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC=CC2=C1CCOC2C3=NCCN3;
	InChI InChI=1S/C13H16N2O2/c1-16-11-4-2-3-10-9(11)5-8-17-12(10)13-14-6-7-15-13/h2-4,12H,5-8H2,1H3,(H,14,15); Key:GHIKYGQWBRHEGU-UHFFFAOYSA-N;

Tasipimidine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ODM-105 and ORM-19695), sold under the brand name Tessie, is an α₂-adrenergic receptor agonist which is approved for the short-term treatment of fear and anxiety in dogs. It is also under development for the treatment of insomnia in humans. The drug is used as an oral solution in dogs, whereas its route of administration for humans is unspecified.

The drug acts as a potent and selective full agonist of the human α_2A-adrenergic receptor. Conversely, it is a much weaker agonist of the rodent α_2B-, α_2C-, and α_2D-adrenergic receptors. In addition, it shows only low affinity for α₁-adrenergic receptors, where it appears to act as a partial agonist. Tasipimidine produces anxiolytic, sedative, hypolocomotor, hypotensive, and bradycardic effects in animals.

Tasipimidine is under development for use in humans by Orion Corporation. As of October 2024, it is in phase 2 clinical trials for this indication. The drug is or was also under development for the treatment of psychiatric disorders in humans, but no recent development for this indication has been reported. It has reached phase 1 trials for psychiatric disorders. Tasipimidine was approved for treatment of fear and anxiety in dogs in the European Union in 2021.